RECURSION PHARMACEUTICALS - PHASE 2 SHOWS 47% MEDIAN POLYP BURDEN REDUCTION, 85% EVALUABLE PATIENTS BELOW BASELINE AFTER 12 WEEKS OFF-TREATMENT

Reuters · 1d ago

Please log in to view news